Pharmaceuticals
HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial
* Significant improvement in Overall Response Rate (83%) compared with matched case control group (45%). * Significant overall survival advantage, with a 46% reduction in the risk of death. * Excellent safety profile and significant efficacy bolster HaemaLogiX's plan to progress further Kap...
2023-06-29 19:00
2370
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer
BEIJING, KYOTO and BOSTON, June 29, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced clinical results of its novel KRAS G12C inhibitor glecirasib monotherapy and in combination therapy with cetuximab to treat KRAS G...
2023-06-29 16:31
2365
Clarity establishes a US Center of Excellence for Targeted Copper Theranostics
SYDNEY, June 28, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the establishment of a ...
2023-06-28 20:58
3017
Sanyou Forms Partnership with Hangzhou Zhongmei Huadong Pharmaceutical, Catalyzing Innovative Drug Research and Development
SHANGHAI, June 28, 2023 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as Sanyou) and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963) (hereinafter referred to asHuadong Medicine), signed...
2023-06-28 20:00
2203
Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite
* CBL-514 is the only non-invasive product that can improve 1-level of cellulite severity two weeks after a single treatment. * The highest dose of CBL-514 treatment demonstrated the best efficacy, 87.5% of thighs achieved at least 1-level improvement in cellulite severity two weeks after CBL...
2023-06-28 18:30
2318
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
HONG KONG, June 27, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltdtogether with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"), a non-wholly owned subsidiary of Company, has received a drug registration approval from the Natio...
2023-06-28 09:57
2543
LYMPHOMA THERAPY NOW APPROVED FOR AUSTRALIAN PATIENTS With Diffuse Large B-cell Lymphoma
MINJUVI® (tafasitamab) provisionally approved by Therapeutic Goods Administration[1] Recent five-year follow-up data from Phase 2 L-MIND investigation showed patients treated with MINJUVI had prolonged, durable responses[2] SINGAPORE, June 27, 2023 /PRNewswire/ -- Independent biopharmaceutical ...
2023-06-28 04:00
2329
EXCELLENT CLINICAL DATA FOR SUBB2M/CA15-3 BREAST CANCER TEST
* INOVIQ's SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) * The results of a comprehensive 483-sample case-control study established that INOVIQ's SubB2M/CA15-3 blood test significantly outperformed a ...
2023-06-27 19:00
2608
HitGen launches a newly upgraded version of OpenDEL™, a self-service screening kit, to facilitate innovative drug discovery research
CHENGDU, China, June 26, 2023 /PRNewswire/ -- HitGen Inc. ("HitGen", SSE: 688222.SH) has recently launched a newly upgraded version of its OpenDEL™ product, a self-service screening kit for novel molecules. It contains 65% more DEL libraries than the previous version, and with over 3 billion comp...
2023-06-26 21:30
3089
SK pharmteco doubles viral vector production capacity in Europe
* Yposkesi, SK pharmteco's clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes its second bioproduction facility and doubles its manufacturing footprint to10,000m2, one of the largest inEurope * Operation of the second facility to kick sta...
2023-06-23 07:30
2825
Bergen Conference Marks 150 Years Since Discovery of the Leprosy Bacillus
TOKYO, June 22, 2023 /PRNewswire/ -- A two-day conference commemorating the discovery of the bacillus that causes leprosy 150 years ago took place in Bergen, Norway, on June 21-22, 2023. Organized by the Sasakawa Leprosy (Hansen's Disease) Initiative and the University of Bergen, the conference i...
2023-06-22 22:00
2671
I-Mab Announces the Appointment of Raj Kannan as CEO
GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan...
2023-06-22 20:00
2982
PSYLO ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH DAIICHI SANKYO TO DEVELOP NON-HALLUCINOGENIC PSYCHIATRIC THERAPIES
The Sponsored Research Agreement will help advance antidepressant treatments for patients in need SYDNEY, June 22, 2023 /PRNewswire/ -- Biotech start-up, Psylo, announced today that it has entered into a Sponsored Research Agreement with global Japanese pharmaceutical company, Daiichi Sankyo (DS...
2023-06-22 19:00
2699
Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry
TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications. The company will supply materials to all global regions, includingAsia such as China, India, Europe,...
2023-06-22 13:00
2365
BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease
WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the initiation of a randomized, placebo-controll...
2023-06-22 08:02
2574
Dr. Yinfei Yin Joins Shanghai ChemPartner as Vice President and Head of Biology and Pharmacology
SHANGHAI, June 21, 2023 /PRNewswire/ -- ChemPartner
2023-06-21 23:07
2989
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan
TOKYO, June 20, 2023 /PRNewswire/ -- Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered inTokyo, Japan (President & CEO, Eiichi Takahashi) has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of...
2023-06-21 09:00
3279
Clarity commences COMBAT theranostic prostate cancer trial in the US
SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its64C...
2023-06-20 21:03
2494
Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023
SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, asthma, ophthalmology and other autoimmune diseases, announced the preliminary phase I data of LP-003 ...
2023-06-20 21:00
2275
Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C. The studies a...
2023-06-20 18:30
5543
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 312 media titles]
2026-02-03 11:00
Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 303 media titles]
2026-02-03 12:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 286 media titles]
2026-02-01 19:35